Prognostic impact of blood urea nitrogen to albumin ratio on patients with sepsis: a retrospective cohort study.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
20 06 2023
Historique:
received: 07 12 2022
accepted: 15 06 2023
medline: 22 6 2023
pubmed: 21 6 2023
entrez: 20 6 2023
Statut: epublish

Résumé

To investigate the ability of the ratio of blood urea nitrogen (BUN) to serum albumin ratio (BAR) in patients with sepsis in intensive care units (ICUs) to predict the prognosis of short-and long-term death. Data are from the Marketplace for Intensive Care Medical Information IV (MIMIC-IV v2.0) database for patients with sepsis as defined by SEPSIS-3. The primary outcome was 30-day mortality and the secondary outcome was 360-day mortality. Kaplan-Meier (KM) survival curves were plotted to describe differences in BAR mortality in different subgroups and area under the curve (AUC) analysis was performed to compare the predictive value of sequential organ failure assessment (SOFA), BAR, blood urea nitrogen (BUN) and albumin. Multivariate Cox regression models and subgroup analysis were used to determine the correlation between BAR and 30-day mortality and 360-day mortality. A total of 7656 eligible patients were enrolled in the study with a median BAR of 8.0 mg/g, including 3837 in the ≤ 8.0 group and 3819 in the BAR > 8.0 group, with 30-day mortality rates of 19.1% and 38.2% (P < 0.001) and 360-day mortality rates of 31.1% and 55.6% (P < 0.001). Multivariate Cox regression models showed an increased risk of death for 30-day mortality (HR = 1.219, 95% CI 1.095-1.357; P < 0.001) and 360-day mortality (HR = 1.263, 95% CI 1.159-1.376; P < 0.001) in the high BAR group compared to the low BAR group. For the 30-day outcome, the area under the curve (AUC) was 0.661 for BAR and 0.668 for 360-day BAR. In the subgroup analysis, BAR remained an isolated risk factor for patient death. As a clinically inexpensive and readily available parameter, BAR can be a valuable forecaster of prognosis in patients with sepsis in the intensive care unit.

Identifiants

pubmed: 37340147
doi: 10.1038/s41598-023-37127-8
pii: 10.1038/s41598-023-37127-8
pmc: PMC10282077
doi:

Substances chimiques

Serum Albumin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10013

Informations de copyright

© 2023. The Author(s).

Références

JAMA. 2010 Oct 27;304(16):1787-94
pubmed: 20978258
Front Artif Intell. 2021 May 31;4:691626
pubmed: 34136802
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
JPEN J Parenter Enteral Nutr. 2019 Feb;43(2):181-193
pubmed: 30288759
Crit Care. 2008;12(4):R110
pubmed: 18755026
Nutr Clin Pract. 2019 Feb;34(1):12-22
pubmed: 30580456
Postgrad Med J. 2019 May;95(1123):240-244
pubmed: 31129625
Kidney Int. 2011 Oct;80(7):760-7
pubmed: 21716258
Crit Care. 2014 Jul 16;18(4):231
pubmed: 25042164
Kidney Int. 2019 Nov;96(5):1083-1099
pubmed: 31443997
Crit Care Med. 2013 Sep;41(9 Suppl 1):S81-98
pubmed: 23989098
J Crit Care. 2016 Jun;33:62-70
pubmed: 26831575
Ann Palliat Med. 2021 Nov;10(11):11653-11663
pubmed: 34872290
EMBO J. 2001 Dec 3;20(23):6712-23
pubmed: 11726507
Nephrol Dial Transplant. 2015 Feb;30(2):169-77
pubmed: 24848133
Int J Gen Med. 2021 Oct 28;14:7349-7359
pubmed: 34737629
Clin Invest Med. 2014 Apr 01;37(2):E58-69
pubmed: 24690420
Am J Emerg Med. 2021 Mar;41:152-157
pubmed: 33465709
Nephrol Dial Transplant. 2008 May;23(5):1569-74
pubmed: 18281319
J Innate Immun. 2017;9(5):441-455
pubmed: 28697503
Int J Gen Med. 2012;5:583-9
pubmed: 22866010
Biol Res Nurs. 2019 May;21(3):237-244
pubmed: 30722677
Nat Rev Immunol. 2008 Oct;8(10):776-87
pubmed: 18802444
Lancet. 2020 Jan 18;395(10219):200-211
pubmed: 31954465
Nat Rev Immunol. 2010 Dec;10(12):826-37
pubmed: 21088683
PeerJ. 2019 Jun 10;7:e7083
pubmed: 31218129
J Vet Emerg Crit Care (San Antonio). 2018 Nov;28(6):503-511
pubmed: 30299568
J Med Virol. 2021 Feb;93(2):786-793
pubmed: 32662893
Ann N Y Acad Sci. 2008 Nov;1144:210-36
pubmed: 19076379
Intensive Care Med. 2019 Dec;45(12):1718-1731
pubmed: 31531715
Intensive Care Med. 2017 Jun;43(6):816-828
pubmed: 28364303
Nat Rev Cardiol. 2021 Jun;18(6):424-434
pubmed: 33473203

Auteurs

Yuhe Wang (Y)

Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Anhui Province Key Laboratory of Clinical and Preclinical Research in Respiratory Disease, Bengbu, China.

Shan Gao (S)

Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Anhui Province Key Laboratory of Clinical and Preclinical Research in Respiratory Disease, Bengbu, China.

Lei Hong (L)

Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Anhui Province Key Laboratory of Clinical and Preclinical Research in Respiratory Disease, Bengbu, China.

Tingting Hou (T)

Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Anhui Province Key Laboratory of Clinical and Preclinical Research in Respiratory Disease, Bengbu, China.

Huihui Liu (H)

Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Anhui Province Key Laboratory of Clinical and Preclinical Research in Respiratory Disease, Bengbu, China.

Meng Li (M)

Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Anhui Province Key Laboratory of Clinical and Preclinical Research in Respiratory Disease, Bengbu, China.

Shu Yang (S)

School of Health Management, Bengbu Medical College, Bengbu, China.

Yong Zhang (Y)

Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Bengbu Medical College, Bengbu, China. zsuzy@126.com.
Anhui Province Key Laboratory of Clinical and Preclinical Research in Respiratory Disease, Bengbu, China. zsuzy@126.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH